Delivery Order SPE2DB22D3501-SPE2DB25FXC76
- Not listed
- This delivery order, valued at $4,651.10, awards AmerisourceBergen Drug Corp the supply of Leqvio 284 mg/1.5 mL syringes under a firm fixed-price contract with the Defense Logistics Agency (DLA). The award was issued on August 5, 2025, with an ultimate completion date of August 26, 2025, and represents a non-competitive delivery order against an existing contract vehicle. Performance will take place at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a $23,255.50 delivery order to AmerisourceBergen Drug Corp for LEQVIO 284 mg/1.5 ml syringes on August 18, 2025, with an ultimate completion date of September 9, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and specifies performance at the contractor's location in Conshohocken, Pennsylvania. LEQVIO is an injectable cardiovascular medication used to lower LDL cholesterol levels, reflecting the Defense...
- The U.S. government agency, the Defense Logistics Agency (DLA) Troop Support Medical, awarded a Delivery Order contract to Amerisourcebergen Drug Corp's Corporate Office Division, a major pharmaceutical distributor, for the procurement of Leqvio 284 mg/1.5 ml syringes. The Firm Fixed Price contract, valued at $21,974.10, has an ultimate completion date of August 5, 2024. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with the DLA, valued up to $999,999,999.00 through...
- The Defense Logistics Agency (DLA) awarded a $34,883.25 delivery order to AmerisourceBergen Drug Corp for the supply of LEQVIO 284 mg/1.5 mL syringes. This competitively awarded, firm fixed-price contract carries an ultimate completion date of August 14, 2025, and will be fulfilled from the vendor's Conshohocken, Pennsylvania location. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999...
- Amerisourcebergen Drug Corp has received a firm fixed price delivery order from the Defense Logistics Agency Troop Support Medical for $13,018.86 to supply 4563033522 LEQVIO 284 MG/1.5 ML SYRINGE 1.5ML. Performance will take place at Amerisourcebergen's facility in Conshohocken, Pennsylvania, with completion by December 29, 2023. This order was awarded against an indefinite delivery contract held by Amerisourcebergen Drug Corp with no set-aside designation used. As a prime contractor,...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $13,953.30 firm fixed-price contract is for the delivery of 4567995177 LEQVIO 284 MG/1.5 ML SYRINGE 1.5ML, with a performance period through May 13, 2025. AmerisourceBergen Drug Corp holds a substantial Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999.00. This IDC, designated...
- The Defense Logistics Agency Troop Support Medical awarded a $13,018.86 firm fixed price delivery order to Amerisourcebergen Drug Corporation for 4562313798 LEQVIO 284 MG/1.5 ML SYRINGE 1.5ML. The place of performance will be Amerisourcebergen's facility located in Conshohocken, Pennsylvania. The delivery order has a period of performance starting on September 26, 2023 through October 18, 2023. As the Defense Logistics Agency is responsible for worldwide logistics support in procurement and...
- This is a $13,953.30 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of LEQVIO 284 MG/1.5 ML SYRINGE 1.5ML. The award is not associated with a set-aside program and has an ultimate completion date of May 5, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which serves as a primary vehicle for providing a...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor, for the supply of LEQVIO 284 MG/1.5 ML SYRINGE 1.5ML. The $4,394.82 firm fixed-price contract has a completion date of September 17, 2024. AmerisourceBergen holds a larger $999,999,999 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical to provide a comprehensive range of medical commodities, including...
- Amerisourcebergen Drug Corporation, a division of Amerisourcebergen Corporation, has been awarded a delivery order valued at $6,509.43 by the Defense Logistics Agency to supply 4561585039 LEQVIO 284 MG/1.5 ML SYRINGES in quantities of 1.5ML each. Performance will take place in Conshohocken, Pennsylvania under firm fixed pricing over a three week period concluding in mid-August. The Defense Logistics Agency utilizes numerous contracts government-wide to facilitate procurement of medical...
- SPE2DB22D3501Indefinite Delivery Contract
- SPE2DB22D3501-SPE2DB25FXC76Delivery Order
The Defense Logistics Agency awarded a $6,976.65 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 1.5 milliliter syringes containing Leqvio 284 mg. The contract, which is not set-aside, was awarded on September 2, 2025, with a completion date of September 23, 2025. Performance will occur at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion comprehensive pharmaceutical supply vehicle running through December 2026 that enables the company to furnish a broad range of medications and medical supplies to support military healthcare programs globally. Leqvio is a PCSK9 inhibitor used to reduce low-density lipoprotein cholesterol in patients with cardiovascular disease. AmerisourceBergen's role as a prime pharmaceutical vendor for DLA reflects its position as a major distributor serving federal medical procurement needs across the Defense Health Agency and other government healthcare systems. The company's competitive award history and expansive contract portfolio demonstrate its capability to meet federal requirements for critical pharmaceutical commodities, including specialty medications, brand-name and generic drugs, and medical devices across multiple therapeutic domains supporting military personnel and veteran healthcare.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.0k | 9/2/25 |